French drugmaker Sanofi to invest €170m to expand seasonal flu vaccine site

Ikaba Koyi Sharecast | 12 Oct, 2017 13:04 | | |

GSK, drugs, lab
  • 83.92
  • -0.37%-0.31
  • Max: 84.55
  • Min: 83.83
  • Volume: 386,618
  • MM 200 : n/a
n/a
  • 15,074.22
  • 0.13%19.55
  • Max: 15,130.63
  • Min: 15,054.67
  • Volume: 0
  • MM 200 : n/a
n/a
  • 18,592.28
  • -0.32%-59.39
  • Max: 18,695.24
  • Min: 18,539.60
  • Volume: 0
  • MM 200 : n/a
n/a
  • 13,224.99
  • 0.23%30.55
  • Max: 13,258.13
  • Min: 13,194.44
  • Volume: 0
  • MM 200 : n/a
n/a
  • 14,119.79
  • 0.25%35.44
  • Max: 14,148.44
  • Min: 14,084.35
  • Volume: 0
  • MM 200 : n/a
n/a
  • 12,579.32
  • 0.02%3.10
  • Max: 12,617.46
  • Min: 12,558.88
  • Volume: 0
  • MM 200 : n/a
n/a
  • 13,845.32
  • 0.33%45.49
  • Max: 13,859.62
  • Min: 13,799.71
  • Volume: 0
  • MM 200 : n/a
n/a
  • 14,609.51
  • 0.26%37.86
  • Max: 14,637.13
  • Min: 14,571.65
  • Volume: 0
  • MM 200 : n/a
n/a

French drugmaker Sanofi said it was investing €170m in effort to expand a vaccine manufacturing site in Val de Reuil, located in France, reinforcing the company's position as a global leader in seasonal flu vaccines.

The new facility, according to Sanofi, will be the only site of its kind in France and enable Sanofi Pasteur, its vaccines global business unit, to expand supply of the VaxigripTetra influenza vaccine to up to 70 countries on six continents.

That vaccine would contain two A strains and two B strains of the influenza virus, as per recommendations by the World Health Organisation, to help tackle the virus.

According to the company, the investment was one of "several major" capital expenditures that it has made in recent years to develop and expand vaccine production capacities across France, the United States and Mexico by 2021, subject to approvals by relevant health authorities.

Vaccine production in the new facility was scheduled to commence in 2022.

David Loew, the executive vice president of Sanofi and head of Sanofi Pasteur said the expansion proved the Pasteur's ability to tackle the health challenge.

"Influenza continues be a major public health problem around the world, causing serious complications, hospitalizations and deaths, mostly for certain high-risk individuals."

"As a global leader in flu vaccines, this expansion reinforces Sanofi Pasteur's ability to tackle this underestimated health challenge."

Meanwhile, Philippe Luscan, the executive vice president of Global Industrial Affairs at Sanofi spoke of the project's ability to bring together the expertise of its staff.

"This project brings together the expertise of our people with our leading industrial know-how and illustrates our commitment to manufacturing excellence solutions.

"Our investment underlines Sanofi's intent to strengthen our industrial capacities in France as a major centre of influenza vaccines production for worldwide markets."

More news

17:10 Berenberg ups Cobham target but says premium valuation "unwarranted"

Despite Cobham share's outperformance over the past six months, Berenberg cautioned clients about the near-term strength of various of the firm's end-markets, alongside operational challenges that would require time to resolve and, for a time, scupper hopes that the dividend would be reinstated.

17:02 Octagonal 'extremely pleased' as it reports record revenue and profits

Octagonal updated the market on its trading on Friday, based on the unaudited interim figures for the six months to 30 September for its wholly-owned subsidiary, Global Investment Strategy UK, saying it was “extremely pleased” with the record revenues and profits achieved.

16:56 Marlowe trading in line as acquisitions integrate 'well'

Support services group Marlowe updated the market on its trading for the six months to 30 September on Friday, saying trading in the first six months of the financial year was in line with board expectations.

16:53 Ncondezi agrees non-binding development offer with CMEC and GE

Ncondezi Energy announced on Friday that it has agreed - in principle - to the terms of a non-binding offer with China Machinery Engineering Corporation and General Electric South Africa to enter into exclusive negotiations to develop, construct and operate the integrated Ncondezi 300MW coal-fired power project and open pit coal mine in Tete, Mozambique.

16:53 Virgin Money's growth prospects not reflected in share price, Barclays says

Analysts at Barclays Research believe Virgin Money's growth prospects are not reflected in the share price.

16:45 Bacanora clears regulatory hurdle at Sonora lithium project

Lithium exploration and development company Bacanora Minerals announced on Friday that the environmental impact statement - the ‘manifestacion de impacto ambiental’ (MIA) - for its flagship Sonora Project in Mexico has been approved by SEMARNAT, the Environment Ministry of Mexico.

16:39 Elektron Technology completes sale of Sheen Instruments

Elektron Technology confirmed it has completed the sale of its wholly-owned subsidiary Sheen Instruments on Friday, to Industrial Physics.

16:34 DX Group narrows loss after tough year

DX Group reported preliminary results for the year on Friday, with revenue rising to £291.9m from £287.9m a year earlier, although EBITDA fell to £7.2m from £18m.

16:49 Gulf Keystone production, exports not impacted by fighting

Gulf Keystone Petroleum, an independent operator and producer in the Kurdistan Region of Iraq, confirmed on Friday that operations continued safely and securely despite political instability in the surrounding region, with average production of 34,525 barrels of oil equivalent per day from the Shaikan oil field since the start of October.

15:59 US existing home sales move higher in September

Existing home sales in the States broke a three-month streak of consecutive declines but were nevertheless labelled "meagre" by some observers, who warned that a lack of supply and fast price increases were putting a crimp in buyers' budgets.